In its Q1 2026 update, PROCEPT BioRobotics Corp demonstrated strong commercial momentum primarily fueled by increasing sales of its AquaBeam and HYDROS robotic systems alongside rising procedure volumes. The company’s core Aquablation therapy, targeting benign prostatic hyperplasia (BPH), leverages proprietary robotics and real-time imaging to offer consistent outcomes unaffected by prostate size or surgeon skill. Supportive clinical evidence and reimbursement coverage fortify its competitive positioning. However, growth hinges on expanded adoption in a still-nascent market, navigating complex reimbursement landscapes, managing supply constraints, and sustaining capital investment. PROCEPT’s ongoing clinical trials aiming at prostate cancer applications and product innovations are crucial growth levers to watch.